[.
]
Action/Kinetics:
Prodrug converted by esterases in the body to the active colterol. Colterol combines with beta-2-adrenergic receptors, producing dilation of bronchioles. Minimal beta-1-adrenergic activity.
Onset following inhalation: 2-4 min.
Time to peak effect: 30-60 min.
Duration: 5-8 hr.
Uses:
Prophylaxis and treatment of bronchial asthma and reversible bronchospasms. May be used with theophylline and/or steroids.
Special Concerns:
Safety has not been established for use during lactation and in children less than 12 years of age. Use with caution in ischemic heart disease, hypertension, hyperthyroidism, diabetes mellitus, cardiac arrhythmias, seizure disorders, or in those who respond unusually to beta-adrenergic agonists. There may be decreased effectiveness in steroid-dependent asthmatic clients. Hypersensitivity reactions may occur.
Additional Side Effects:
CNS: Hyperactivity, hyperkinesia, lightheadedness, tremor, dizziness, vertigo, nervousness, tension, headache, insomnia.
CV: Premature ventricular contractions, palpitations, tachycardia, hypertension, chest tightness/pain/discomfort, angina.
Respiratory: Dry throat, throat irritation, pharyngitis, cough, dyspnea, bronchospasm.
Other: N&V;, flushing.
Laboratory Test Alterations:
AST.
Platelets, WBCs. Proteinuria.
Drug Interactions:
Additive effects with other beta-adrenergic bronchodilators.
How Supplied:
Aerosol 0.37 mg/inh;
Solution for Inhalation: 0.2%
Dosage
?Aerosol
Bronchospasm.
Adults and children over 12 years: 2 inhalations at an interval of 1-3 min (if necessary, a third inhalation may be taken). Do not exceed 3 inhalations q 6 hr or 2 inhalations q 4 hr.
Prophylaxis of bronchospasm.
Adults and children over 12 years: 2 inhalations q 8 hr.
Note: Usual frequency is t.i.d.; can increase to q.i.d. but interval between treatments should be 4 hr or more.
